Patent · US Active

Combination of anti-CD20 antibody and PI3 kinase selective inhibitor

US9694071B2 · kind B2 · utility

5Cited by

1References

25Claims

0Family size

Assignees

TG Therapeutics, Inc. · US
RHIZEN PHARMACEUTICALS AG · CH
Laboratoire Francais du Fractionnement et des Biotechnologies · FR

Inventors

Michael S. Weiss · New York, US
Hari P. Miskin · New York, US
Peter Sportelli · New York, US
Swaroop K.V.S. Vakkalanka · La Chaux-de-Fonds, CH

Key dates

Filing date	Nov 1, 2013
Grant date	Jul 4, 2017
Priority date	—
Expiry date	Dec 26, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/73
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Highly effective combinations of a compound of formula A (a PI3Kδ selective inhibitor) and anti-CD20 antibodies are provided herein for the treatment and amelioration of PI3Kδ and/or CD20 mediated diseases and disorders. In particular, the combination can be used to treat cancers and autoimmune diseases. More particularly, the invention provided for a combination of a compound of formula A, or stereoisomers thereof, and ublituximab for the treatment and/or amerioration of hematological malignancies such as leukemia and lymphoma.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.